Skip to main content
. Author manuscript; available in PMC: 2022 May 12.
Published in final edited form as: Nat Aging. 2021 Dec 6;1(12):1175–1188. doi: 10.1038/s43587-021-00138-z

Extended Data Fig 3. The efficacy of endophenotype-based drug repurposing in Alzheimer’s disease (AD).

Extended Data Fig 3.

Molecular targets of 21 ongoing repurposable AD drugs that target both Amyloid and Tau have significantly closer network distance with AD network modules built from transcriptomics (a) and proteomics (b) data from AD genetic mouse, in comparison to drugs targeting amyloid or tau alone. In a, we built AD modules from 34 differentially expressed gene sets derived from transcriptomics data (including microarray, and bulk RNA-sequencing) from AD genetic mouse. In b, we built AD modules for 10 differentially expressed protein sets from proteomics data in AD genetic mice. P values were calculated by Wilcoxon test (one-side) in a and b.